Ramy Riad: Advancing Plasma-Derived Therapies Through Partnership
Ramy Riad, President of Plasma-Derived Therapies Business Unit at Takeda, shared a post on LinkedIn:
“Wrapping up a productive first day at IPPC 2026, hosted by Plasma Protein Therapeutics Association (PPTA), with a real sense of momentum.
This year’s theme — ‘Resilience, Reach and Responsibility’ — perfectly captures the leadership imperative facing our industry.
No single organization can sustain the plasma ecosystem alone.
It requires long‑term partnerships and shared responsibility across the value chain.
Today’s conversations reinforced how essential collaboration is to protect access for the patients who depend on plasma-derived therapies.
Looking forward to the sessions ahead and to connecting with fellow leaders shaping the future of plasma.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support